Nia Impact Advisors, LLC Editas Medicine, Inc. Transaction History

Nia Impact Advisors, LLC

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 09, 2023	SELL	$8.32 - $13.21 $87,260 - $138,546	-10,488 Reduced 42.95%	13,931 $123,000
Q3 2022 Nov 14, 2022	SELL	$12.16 - $19.42 $854,653 - $1.36 Million	-70,284 Reduced 74.22%	24,419 $299,000
Q2 2022 Aug 05, 2022	SELL	$9.99 - $21.35 $594,914 - $1.27 Million	-59,551 Reduced 38.61%	94,703 $1.12 Million
Q1 2022 May 11, 2022	BUY	$14.08 - $27.63 $920,564 - $1.81 Million	65,381 Added 73.57%	154,254 $2.93 Million
Q4 2021 Feb 11, 2022	BUY	$26.55 - $40.57 $176,265 - $269,344	6,639 Added 8.07%	88,873 $1.54 Million
Q3 2021 Nov 16, 2021	BUY	$39.27 - $72.94 $466,134 - $865,797	11,870 Added 16.87%	82,234 $3.38 Million
Q2 2021 Aug 16, 2021	BUY	$31.29 - $56.64 $165,211 - $299,059	5,280 Added 8.11%	70,364 $3.99 Million
Q1 2021 Jun 16, 2021	BUY	$39.71 - $90.58 $415,723 - $948,282	10,469 Added 19.17%	65,084 $2.73 Million
Q4 2020 Jan 25, 2021	BUY	$27.07 - $84.35 $1.48 Million - $4.61 Million	54,615 New	54,615 $4.9 Million

244

56.8M

410K

394K

Ticker EDIT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 68,737,200
Market Cap $90M
Description
Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary gene editing platform based on CRISPR technology. The company develops EDIT-101, which is in Phase 1/2 clinical trial for Leber Congenital Amaurosis 10 that leads t...

Get notified when there are updates to the investment portfolio of Nia Impact Advisors, LLC, based on Form 13F filings with the SEC.

Stay updated on Nia Impact Advisors, LLC with notifications on news.